SkinHealth Systems launches SkinStylus in six European markets

The move marks the first international expansion of SkinStylus since SkinHealth Systems acquired the device in 2023. CEO Pedro Malha framed the launch as part of building "a broader medical aesthetics ecosystem," leveraging the company's existing Hydrafacial commercial infrastructure and provider relationships across Europe to distribute the new technology.

SkinStylus is engineered as a professional microneedling system with adjustable settings and multiple SteriLock cartridge options. The device creates controlled microchannels in the skin using an array of fine needles. According to the company, the treatment addresses fine lines, wrinkles, uneven texture, and overall skin quality with minimal downtime. The nano-needling feature may also help professional topical skincare products absorb into the skin during treatment.

Trained aesthetic professionals can adjust treatments based on each client's cosmetic skin concerns, needs, and desired outcomes through the device's range of options. The company describes SkinStylus as engineered for precision, consistency and to build practitioner confidence.

The company positions SkinStylus as complementary to Hydrafacial rather than competitive. Hydrafacial treatments support ongoing skin health maintenance, while SkinStylus microneedling renews and rejuvenates skin. This pairing gives aesthetic professionals two distinct tools to address a wider range of client concerns within a single provider relationship.

SkinHealth Systems will sell SkinStylus through its direct European commercial organization initially. The company expects to expand into select distributor markets beginning in 2027, though the document does not specify which countries or regions those will be.

The timing arrives as SkinHealth Systems faces revenue headwinds. Q2 2026 revenues were $72.1 million, down 7.79% year-over-year. Institutional investor sentiment has also shifted: 69 institutional investors decreased their positions in the most recent quarter, while 33 added shares. Analysts have issued a median price target of $1.50 for the stock, with only two analysts offering targets in the last six months.

The company's broader portfolio includes HydraScalp with Keravive, a scalp treatment offering, alongside its flagship Hydrafacial brand. SkinHealth Systems describes itself as delivering "an integrated ecosystem of clinically proven solutions" through an omnichannel network of providers worldwide.

Microneedling itself is a nonsurgical, minimally invasive cosmetic procedure. A qualified provider uses an array of fine needles to create the controlled microchannels. The process refreshes the skin and helps diminish fine lines, wrinkles, uneven texture, and overall skin quality. The company emphasizes minimal downtime as a benefit for clients.

The document does not specify whether SkinStylus has received CE marking or other regulatory clearance in the European markets where it is now being sold. It also does not disclose pricing, expected revenue contribution, specific distributor partners for the 2027 expansion, or how the European launch will affect overall company financials. The company's forward-looking statements acknowledge risks including how providers and consumers view SkinStylus, regulatory factors affecting the ability to sell the device in European countries and through distributor markets, and the success of the product launch in each respective country.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.